[1. FISHER B.A., BROWN R.M., BOWMAN S.J., BARONE F. A review of salivary gland histopathology in primary Sjögren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015; 74:1645–50.10.1136/annrheumdis-2015-20749926034044]Search in Google Scholar
[2. CHERIF E., BOUKHRIS I., HAJJI R., HASSINE LB., AZZABI S., KECHAOU I. et al. Extra-glandular manifestations of primary Sjögren’s syndrome. Eur J Intern Med. 2013; 24:e119.10.1016/j.ejim.2013.08.302]Search in Google Scholar
[3. ATTWOOD W., POSER CM. Neurologic complications of Sjogren’s syndrome. Neurology. 1961; 11:1034–41.10.1212/WNL.11.12.103413863143]Search in Google Scholar
[4. PAVLAKIS P.P., ALEXOPOULOS H., KOSMIDIS M.L., MAMALI I., MOUTSOPOULOS H.M., TZIOUFAS A.G. et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012; 39:27–33.10.1016/j.jaut.2012.01.00322318209]Search in Google Scholar
[5. MARGARETTEN M. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018; 56:99–105.10.5114/reum.2018.75521597463229853725]Search in Google Scholar
[6. DELALANDE S., DE SEZE J., FAUCHAIS A.-L., HACHULLA E., STOJKOVIC T., FERRIBY D. et al. Neurologic manifestations in primary Sjögren syndrome. Medicine (Baltimore). 2004; 83:280–91.10.1097/01.md.0000141099.53742.1615342972]Search in Google Scholar
[7. MOROZUMI S., KAWAGASHIRA Y., IIJIMA M., KOIKE H., HATTORI N., KATSUNO M. et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren’s syndrome. J Neurol Sci. 2009; 279:57–61.10.1016/j.jns.2008.12.01819168191]Search in Google Scholar
[8. LEVY Y., UZIEL Y., ZANDMAN G.G., AMITAL H., SHERER Y., LANGEVITZ P. et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003; 62:1221–3.10.1136/ard.2002.003996175438514644864]Search in Google Scholar
[9. MOCHIZUKI H., KAMAKURA K., MASAKI T., HIRATA A., NAKAMURA R., MOTOYOSHI K. Motor dominant neuropathy in Sjoegren’s syndrome: Report of two cases. Intern Med. 2008; 41:142–6.10.2169/internalmedicine.41.14211868603]Search in Google Scholar
[10. FONT J., RAMOS-CASALS M., DE LA RED G., POU A., CASANOVA A., GARCIA-CARRASCO M. et al. Pure sensory neuropathy in primary Sjögren’s syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003; 30:1552–7.]Search in Google Scholar
[11. RIST S., SELLAM J., HACHULLA E., SORDET C., PUECHAL X., HATRON P. et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: A national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011; 63:1339–44.10.1002/acr.2049521584943]Search in Google Scholar
[12. PERTOVAARA M., KORPELA M. Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy. Clin Exp Rheumatol. 2012; 30:808.]Search in Google Scholar
[13. MEKINIAN A., RAVAUD P., HATRON P.Y., LARROCHE C., LEONE J., GOMBERT B. et al. Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012; 71:84–7.10.1136/annrheumdis-2011-20008621926185]Search in Google Scholar
[14. MIN J.K., PARK K.S., YU W.J., LEE Y.S., PARK S.M., PARK S.H. et al. Systemic mononuclear inflammatory vasculopathy associated with Sjögren’s syndrome in a patient with primary biliary cirrhosis. Korean J Intern Med. 2000; 15:89–92.10.3904/kjim.2000.15.1.89453175110714099]Search in Google Scholar
[15. SHIMOYAMA M., OHTAHARA A., OKAMURA T., WATANABE M., FUJIMOTO Y., TESHIMA S. et al. Isolated autonomic cardiovascular neuropathy in a patient with primary Sjögren syndrome: a case of successful treatment with glucocorticoid. Am J Med Sci. 2002; 324:170–2.10.1097/00000441-200209000-0001012240717]Search in Google Scholar
[16. DUPOND J.L., GIL H., DE WAZIERES B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjögren’s syndrome. Am J Med. 1999; 106:125.]Search in Google Scholar
[17. PASCUAL J., CID C., BERCIANO J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjögren’s syndrome. Neurology. 1998; 51:650–1.10.1212/WNL.51.2.650-b]Search in Google Scholar
[18. KIZAWA M., MORI K., IIJIMA M., KOIKE H., HATTORI N., SOBUE G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 2006; 77:967–9.10.1136/jnnp.2005.084533207761316844955]Search in Google Scholar
[19. MOLINA J.A., BENITO-LEÓN J., BERMEJO F., JIMÉNEZ-JIMÉNEZ F.J., OLIVÁN J. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 1996; 60:699.10.1136/jnnp.60.6.69910739668648349]Search in Google Scholar
[20. TAKAHASHI Y., TAKATA T., HOSHINO M., SAKURAI M., KANAZAWA I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome. IV immunoglobulin. Neurology. 2003; 60:503–5.10.1212/01.WNL.0000046680.47883.7D]Search in Google Scholar
[21. MORI K., IIJIMA M., KOIKE H., HATTORI N., TANAKA F., WATANABE H. et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005; 128:2518–34.10.1093/brain/awh60516049042]Search in Google Scholar
[22. GORSON K.C., NATARAJAN N., ROPPER A.H., WEINSTEIN R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve. 2007; 35:66–9.10.1002/mus.2066416967492]Search in Google Scholar
[23. BOTEZ S.A., HERRMANN D.N. Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren’s syndrome after Rituximab therapy. J Clin Neuromuscul Dis. 2010; 11:127–31.10.1097/CND.0b013e3181c5051320215986]Search in Google Scholar
[24. MEIJER J.M., MEINERS P.M., VISSINK A., SPIJKERVET F.K.L., ABDULAHAD W., KAMMINGA N. et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010; 62:960–8.10.1002/art.2731420131246]Search in Google Scholar
[25. VOULGARELIS M., GIANNOULI S., TZIOUFAS A.G., MOUTSOPOULOS H.M. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006; 65:1033–7.10.1136/ard.2005.046193179823516322082]Search in Google Scholar
[26. MOHER D., LIBERATI A., TETZLAFF J., ALTMAN D.G., GROUP T.P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009; 6:e1000097.10.1371/journal.pmed.1000097270759919621072]Search in Google Scholar
[27. WAKASUGI D., KATO T., GONO T., ITO E., NODERA H., KAWAGUCHI Y. et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren’s syndrome. Mod Rheumatol. 2009; 19:437–40.10.3109/s10165-009-0180-2]Search in Google Scholar